Find relevant news articles from other European projects, below:
Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:
Looking to Novel Immunotherapeutics in Relapsed/Refractory Multiple Myeloma
Marc J. Braunstein, MD, PhD, discusses the evolution and promise of immunotherapeutics in multiple myeloma.
Dr. Solomon on the Effects of Liso-Cel in Prior Anti-CD19 Therapy–Treated B-NHL
Scott R. Solomon, MD, discusses the effects of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell non-Hodgkin lymphoma who were previously treated with CD19-directed therapies.
Can BiTE Molecules Make Off-the-Shelf Immuno-Oncology a Reality?
In hematologic malignancies, a new class of molecules is emerging that may ultimately offer clinical benefits comparable to those chimeric antigen receptor T-cell therapies while reducing some of the negatives associated with them.
Key Takeaways from the First-in-Human Study of Odronextamab in B-cell NHL
Rajat Bannerji, MD, PhD, discussed key takeaways from the phase 1 study of the novel CD20xCD3 bispecific antibody, odronextamab in patients with highly refractory B-cell non-Hodgkin lymphoma.
CAR-T Meeting 2021 | CAR-T vs. BiTEs in B-cell malignancies
Marion Subklewe, MD, LMU Hospital Munich, Munich, Germany, compares CAR T-cells to bispecific T-cell engagers (BiTEs). Firstly, Prof. Subklewe highlights that there are no randomized trials in any disease comparing CAR T-cells to BiTEs.
HDP-101, an antibody-targeted amanitin conjugate to advance to phase I/IIa testi...
The U.S. Food and Drug Administration (FDA) has announced that the B-cell maturation antigen (BCMA) antibody–drug conjugate HDP-101 can proceed to phase I/IIa testing.
Prof Robin Foà comments on NEJM paper “Dasatinib - Blinatumomab for Ph+ ALL in A...
Listen to Prof. Robin Foà commenting on the rationale and the results of a highly relevant paper published on the New England Journal of Medicine, and reporting an innovative “chemo-free” approach for Ph+ ALL patients. Robin Foà, first author of the paper, highlights the main findings and scientific implications of a clinical trial involving 63 newly diagnosed adult patients with Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL).
AEMPS authorises Hospital Clínic's CAR-T ARI-0001 for patients with acute lympho...
The Spanish Agency of Medicines and Medical Devices (AEMPS) has approved CAR-T ARI-0001, developed by Hospital Clínic, as an advanced therapy drug of non-industrial production for its use in patients over 25 years of age with lymphoblastic leukaemia that is resistant to conventional treatments. It is the first CAR-T developed entirely in Europe to be approved by a regulatory agency.
T2EVOLVE: breakthrough alliance boosting Europe to the forefront of cancer immun...
T2EVOLVE is a new breakthrough alliance of academic and industry leaders in cancer immunotherapy under the European Union's Innovative Medicines Initiative (IMI). The key objective of T2EVOLVE is to accelerate development and increase awareness and access of cancer patients to immunotherapy with immune cells that harbor a genetically engineered T cell receptor (TCR) or synthetic chimeric antigen receptor (CAR). Simultaneously, T2EVOLVE aims to provide guidance on sustainable integration of these treatment into the EU healthcare system.
Keytruda Closer to Expanded EU Approval for Pediatric Resistant Hodgkin’s Lympho...
Keytruda (pembrolizumab) has been recommended for approval in the European Union (EU) to treat adults and children, 3 years and older, with relapsed or refractory classical Hodgkin’s lymphoma (cHL) whose disease failed to respond to autologous stem cell transplant (ASCT) or who received at least two prior therapies when ineligible for ASCT.